It is known that dipeptidyl peptidase-4 (DPP-4) leads to the inactivation of GLP-1; thus, DPP-4 inhibitors lead to increased levels of GLP-1 and have been usefully adapted in various AD animal models [24,25]. The gene discussed is GLP1R; the disease is Alzheimer disease.